<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1260">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04475601</url>
  </required_header>
  <id_info>
    <org_study_id>COVIDENZA</org_study_id>
    <nct_id>NCT04475601</nct_id>
  </id_info>
  <brief_title>Enzalutamide Treatment in COVID-19</brief_title>
  <acronym>COVIDENZA</acronym>
  <official_title>A Prospective, Multicenter, Randomized PHASE II Clinical Trial of Enzalutamide Treatment to Decrease the Morbidity in Patients With Corona Virus Disease 2019 (COVID-19)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Andreas Josefsson</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Umeå University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sahlgrenska University Hospital, Sweden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Umeå</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Uppsala University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Skane University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jonkoping County Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sundsvall Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Helsingborgs Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Göteborg University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Astellas Pharma Europe Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Norrlands University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Västerbotten County Council</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      COVID-19 is a disease with high rate of morbidity if symptomatic. There is a great need of
      treatments to decrease the severity. The vast majority of patients needing intensive care are
      men, and this may be due to the androgens, either by regulation of TMPRSS2, necessary for
      virus internalization, or other mechanisms. Enzalutamide is an antiandrogen inhibiting the
      expression of androgen regulated proteins, such as TMPRSS2. The aim of this trial is to
      evaluate a possible beneficial effect of short-term enzalutamide treatment of COVID-19
      patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 15, 2020</start_date>
  <completion_date type="Anticipated">May 8, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 8, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective, randomized (2:1), open, multicentre, clinical controlled trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to worsening of disease</measure>
    <time_frame>Up to 30 days after inclusion</time_frame>
    <description>Clinical worsening to invasive mechanical ventilation or death as assessed by the 7-point ordinal scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to improvement of disease</measure>
    <time_frame>Up to 30 days after inclusion</time_frame>
    <description>Time to discharge from hospital assessed by the 7-point ordinal scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Safety evaluation, as measured by AEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of supplemental oxygen (days)</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>Total days of extra oxygen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Admission to ICU</measure>
    <time_frame>Up to 30 days and up to 6 months</time_frame>
    <description>Frequence of admission to ICU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory assessment of Hemoglobin concentration day 0, 2, 4 and 6</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>Changes of laboratory parameters: Hb</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virus load assessment day 0, 2, 4 and 6</measure>
    <time_frame>UP to 7 days</time_frame>
    <description>PCR based SARS-CoV-2 measurement from upper respiratory tract</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital stay (days)</measure>
    <time_frame>Up to30 days and 6 months</time_frame>
    <description>Total number of days evaluated at 30 days and 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Re-admission to hospital due to rebound COVID-19</measure>
    <time_frame>Evaluated for 30 days and after 6 months</time_frame>
    <description>If admitted to hospital due to COVID-19 disease after discharge from hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality at 6 months</measure>
    <time_frame>up to 30 days and up to 6 months respectively</time_frame>
    <description>Death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hormonal status at 6 months</measure>
    <time_frame>from baseline to 6 months</time_frame>
    <description>Testosterone and estrogen levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serological immunity for COVID-19</measure>
    <time_frame>At 6 months</time_frame>
    <description>Identification of serologic immunity based after 6 months from inclusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory assessment of CRP concentration day 0, 2, 4 and 6</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>Changes of laboratory parameters: CRP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory assessment of liver function day 0, 2, 4 and 6</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>Changes of laboratory parameters: ALAT, ASTA and/or ALP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory assessment of creatinine concentration day 0, 2, 4 and 6</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>Changes of laboratory parameters: Createnin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory assessment of D-dimer concentration day 0, 2, 4 and 6</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>Changes of laboratory parameters: D-dimer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory assessment of platelets concentration day 0, 2, 4 and 6</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>Changes of laboratory parameters: TPK</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory assessment of IL-6 concentration day 0, 2, 4 and 6</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>Changes of laboratory parameters: IL-6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory assessment of B- and T-lyphocytes concentration day 0, 2, 4 and 6</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>Changes of laboratory parameters: Differentiate count of leucocytes</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>COVID-19</condition>
  <condition>Corona Virus Infection</condition>
  <arm_group>
    <arm_group_label>Enzalutamide+Standard of Care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Up to 5 days with 4x40 mg enzalutamide tablets orally once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard of care</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enzalutamide Pill</intervention_name>
    <description>The once daily dose will be given only during hospitalization and stop if starting invasive mechanical ventilation or at discharge from hospital</description>
    <arm_group_label>Enzalutamide+Standard of Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Positive COVID-19 test

          -  Mild to severe symptoms of COVID-19

          -  Hospitalization

          -  WHO performance status 0-3

          -  Age above or equal to 50 years

          -  Can understand all the requirements of the study, provide informed consent, and
             provide authorization of use and disclosure of personal health information.

          -  Estimated expected survival of 1 year (excluding symptoms due to COVID-19)

        Exclusion Criteria:

          -  Severe allergy to Enzalutamide

          -  Pregnant or breast-feeding women

          -  Need of immediate mechanical ventilation

          -  Current medication includes enzalutamide treatment

          -  Stroke or Transitory Ischemic attack in medical history

          -  Treatment for HIV

          -  Treatment with tamoxifen

          -  Treatment with immunosuppressive agents

          -  Severe immunosuppressive disease

          -  Treatment with warfarin or NOAC (Non-vitamin K-antagonist anticoagulants)

          -  Previous seizure in medical history

          -  Other serious illness or medical condition

          -  Unstable cardiovascular disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas Josefsson, MdPhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Norrlands University Hospital, Region Västerbotten</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andreas Josefsson, MDPhD</last_name>
    <phone>+46 70 3805395</phone>
    <email>andreas.josefsson@umu.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Karin Welén, Assoc. Professor</last_name>
    <phone>+46 706102231</phone>
    <email>karin.welen@urology.gu.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Anders Bjartell</name>
      <address>
        <city>Malmö</city>
        <state>Skåne</state>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anders Bjartell, MD/Prof</last_name>
    </contact>
    <investigator>
      <last_name>Anders Bjartell</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anna Nilsson</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ryhovs Hospital</name>
      <address>
        <city>Jönköping</city>
        <state>Småland</state>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Robinsson, MDPhD</last_name>
    </contact>
    <investigator>
      <last_name>David Robinsson, MDPhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anna Henningsson Jonsson, MDPhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <link>
    <url>http://covidenza.se</url>
    <description>Homepage of the trial</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 8, 2020</study_first_submitted>
  <study_first_submitted_qc>July 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 17, 2020</study_first_posted>
  <last_update_submitted>July 16, 2020</last_update_submitted>
  <last_update_submitted_qc>July 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Västerbotten County Council</investigator_affiliation>
    <investigator_full_name>Andreas Josefsson</investigator_full_name>
    <investigator_title>Assistant Professor and Consultant Urologist</investigator_title>
  </responsible_party>
  <keyword>Enzalutamide</keyword>
  <keyword>Randomized clinical trial</keyword>
  <keyword>COVID-19</keyword>
  <keyword>Sars-CoV2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>The extent of sharing will be regulated during the trial to consider the integrity of the data according GDPR and national laws</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

